TWI780061B - 吲哚啉酮化合物之用途 - Google Patents

吲哚啉酮化合物之用途 Download PDF

Info

Publication number
TWI780061B
TWI780061B TW106125399A TW106125399A TWI780061B TW I780061 B TWI780061 B TW I780061B TW 106125399 A TW106125399 A TW 106125399A TW 106125399 A TW106125399 A TW 106125399A TW I780061 B TWI780061 B TW I780061B
Authority
TW
Taiwan
Prior art keywords
alkyl
group
compound
pharmaceutically acceptable
composition
Prior art date
Application number
TW106125399A
Other languages
English (en)
Chinese (zh)
Other versions
TW201806624A (zh
Inventor
布萊恩 樂努堤
凱特洋 詹森
詹姆士 布萊德利 布萊特米爾
Original Assignee
美商英克特諾治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商英克特諾治療公司 filed Critical 美商英克特諾治療公司
Publication of TW201806624A publication Critical patent/TW201806624A/zh
Application granted granted Critical
Publication of TWI780061B publication Critical patent/TWI780061B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW106125399A 2016-07-29 2017-07-28 吲哚啉酮化合物之用途 TWI780061B (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201662368707P 2016-07-29 2016-07-29
US62/368,707 2016-07-29
US201662417572P 2016-11-04 2016-11-04
US62/417,572 2016-11-04
US201662422504P 2016-11-15 2016-11-15
US62/422,504 2016-11-15
US201662426107P 2016-11-23 2016-11-23
US62/426,107 2016-11-23
US201762503238P 2017-05-08 2017-05-08
US62/503,238 2017-05-08
US201762534067P 2017-07-18 2017-07-18
US62/534,067 2017-07-18

Publications (2)

Publication Number Publication Date
TW201806624A TW201806624A (zh) 2018-03-01
TWI780061B true TWI780061B (zh) 2022-10-11

Family

ID=61011754

Family Applications (2)

Application Number Title Priority Date Filing Date
TW106125399A TWI780061B (zh) 2016-07-29 2017-07-28 吲哚啉酮化合物之用途
TW111135922A TWI857351B (zh) 2016-07-29 2017-07-28 吲哚啉酮化合物之用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW111135922A TWI857351B (zh) 2016-07-29 2017-07-28 吲哚啉酮化合物之用途

Country Status (11)

Country Link
US (4) US10159660B2 (https=)
EP (1) EP3490553B1 (https=)
JP (3) JP6885629B2 (https=)
KR (2) KR20210095721A (https=)
CN (2) CN114569606B (https=)
CA (1) CA3029851A1 (https=)
MX (1) MX395539B (https=)
PH (1) PH12019500070A1 (https=)
SG (1) SG11201811661TA (https=)
TW (2) TWI780061B (https=)
WO (1) WO2018022771A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108580B (zh) * 2014-10-09 2020-06-30 英克特诺治疗公司 吲哚酮化合物及其用途
EP3795563B1 (en) 2016-03-31 2024-07-17 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
CA3029851A1 (en) * 2016-07-29 2018-02-01 Oncternal Therapeutics, Inc. Uses of indoline compounds such as tk216 for the treatment of cancer
CN110818611B (zh) * 2018-08-13 2023-01-24 中国科学院上海药物研究所 一类吲哚酮类化合物、其制备方法、药物组合物和用途
CA3133376A1 (en) * 2018-11-30 2020-06-04 Aptose Biosciences Inc. Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations
WO2022060856A2 (en) * 2020-09-17 2022-03-24 Oklahoma Medical Research Foundation Inhibition of endothelial ets family transcription factors promotes flow-dependent ocular vessel regression
WO2022266491A1 (en) * 2021-06-18 2022-12-22 University Of Maryland, Baltimore Proteolysis targeting chimeras and polypharmacological agents targeting bcl-2, and methods of use thereof
US12447163B2 (en) 2021-07-16 2025-10-21 Jazz Pharmaceuticals Therapeutics, Inc. Liposomal formulations of Bcl inhibitors
WO2025137592A2 (en) * 2023-12-21 2025-06-26 Anuj Bellare Diazirine monomers and polymer compositions derived therefrom
WO2025235561A1 (en) * 2024-05-08 2025-11-13 Enspire Group LLC Venetoclax oral drugs and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057698A1 (en) * 2014-10-09 2016-04-14 Tokalas, Inc. Indolinone compounds and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU583793B2 (en) 1983-07-22 1989-05-11 Du Pont Pharmaceuticals Company Phenylquinolinecarboxylic acids and derivatives as antitumor agents
EP1135123B1 (en) 1998-12-04 2004-12-29 Neurosearch A/S Use of isatin derivatives as ion channel activating agents
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
ES2243461T3 (es) 2000-02-28 2005-12-01 Sugen, Inc. Compuestos de 3-(pirolillactona) -2-indolinona como inhibidores quinasa.
CN1155572C (zh) 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US20030157486A1 (en) 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
US7674778B2 (en) 2004-04-30 2010-03-09 Alnylam Pharmaceuticals Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
US20090217390A1 (en) 2005-04-29 2009-08-27 Fernando Lecanda Cordero Non-human animal sarcoma model
WO2008046083A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
CA2953987A1 (en) 2006-12-29 2008-07-10 Georgetown University Targeting of ews-fli1 as anti-tumor therapy
MX2009011281A (es) 2007-04-20 2010-03-08 Univ New York State Res Found Benzimidazol y composiciones farmaceuticas del mismo.
US8377992B2 (en) 2007-10-22 2013-02-19 The Wistar Institute TRBD-binding effectors and methods for using the same to modulate telomerase activity
US20110218155A1 (en) 2008-10-10 2011-09-08 Dana-Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
AU2009308516B2 (en) 2008-10-21 2016-08-25 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
US8710068B2 (en) 2009-01-19 2014-04-29 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2012078519A2 (en) 2010-12-06 2012-06-14 Numerate, Inc. 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
CN102516152B (zh) 2011-12-12 2014-12-10 华东师范大学 一种α-二氟羰基取代的手性叔醇类化合物及其合成方法和应用
US20130259927A1 (en) 2012-04-02 2013-10-03 Gradalis, Inc. Ewing's Sarcoma Bifunctional shRNA Design
CN107011242B (zh) 2012-04-12 2020-08-07 乔治城大学 用于治疗尤文肉瘤家族肿瘤的方法和组合物
MX2015000804A (es) 2012-07-20 2016-03-11 Star Biotechnology Llc Composiciones y metodos para tratar el sarcoma de ewing y otros trastornos relacionados con ews-fli1.
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
HK1215374A1 (zh) 2013-04-08 2016-08-26 Pharmacyclics Llc 依鲁替尼联合疗法
EA027139B1 (ru) * 2013-04-26 2017-06-30 Бейджин, Лтд. Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны
KR101500363B1 (ko) * 2013-07-01 2015-03-16 현대자동차 주식회사 하이브리드 자동차의 동력전달장치
KR20160037201A (ko) * 2013-08-06 2016-04-05 온코에틱스 게엠베하 Bet-브로모도메인 억제제를 사용한 미만성 거대 b-세포 림프종 (dlbcl)의 치료 방법
CN103435606A (zh) 2013-08-22 2013-12-11 中国药科大学 CDK2与GSK3β双重抑制剂及用途
AU2014340398A1 (en) 2013-10-24 2016-06-09 Georgetown University Methods and compositions for treating cancer
JP6508785B2 (ja) * 2013-10-25 2019-05-08 ファーマサイクリックス エルエルシー ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
CN105960239A (zh) * 2013-11-27 2016-09-21 翁科埃斯克斯有限公司 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法
WO2015082583A1 (en) * 2013-12-05 2015-06-11 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
EP3131552B1 (en) * 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015187848A1 (en) * 2014-06-04 2015-12-10 Sampath Deepa Hdac inhibitor and btk inhibitor combinations
WO2016014859A1 (en) * 2014-07-25 2016-01-28 Pharmacyclics Llc Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
CN107427524A (zh) * 2014-08-28 2017-12-01 翁科埃斯克斯有限公司 利用包含噻吩并三唑并二氮杂*化合物的药物组合物治疗急性髓细胞白血病或急性淋巴性白血病的方法
EP3795563B1 (en) 2016-03-31 2024-07-17 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
CA3029851A1 (en) 2016-07-29 2018-02-01 Oncternal Therapeutics, Inc. Uses of indoline compounds such as tk216 for the treatment of cancer
US20190255127A1 (en) 2018-02-21 2019-08-22 Batu Biologics, Inc. Augmentation of Oncolytic Viral Efficacy through Immunological Targeting Tumor Endothelial Cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057698A1 (en) * 2014-10-09 2016-04-14 Tokalas, Inc. Indolinone compounds and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
期刊 Chen Y, et al. "Lenalidomide as a novel treatment of acute myeloid leukemia." Expert Opin Investig Drugs. 2013 Mar; 22(3): 389-97.; *
期刊 Pon JR, et al. "Clinical impact of molecular features in diffuse large B-cell lymphoma and follicular lymphoma." Blood 2016; 127(2): 181-186 (Prepublished online as Blood First Edition paper, October 7, 2015) *
網路文獻 AbbVie News Center, "AbbVie receives EMA orphan drug designation for investigational compound venectoclax for the treatment of acute myeloid leukemia (AML)", 2016/2/26. https://news.abbvie.com/news/abbvie-receives-ema-orphan-drug-designation-for-investigational-compound-venetoclax-for-treatment-acute-myeloid-leukemia-aml.htm "AbbVie receives EMA orphan drug designation for investigational com; *

Also Published As

Publication number Publication date
EP3490553A4 (en) 2020-03-25
JP2021050227A (ja) 2021-04-01
US10646470B2 (en) 2020-05-12
EP3490553B1 (en) 2024-08-28
JP2019522037A (ja) 2019-08-08
TW201806624A (zh) 2018-03-01
EP3490553A1 (en) 2019-06-05
US20180028495A1 (en) 2018-02-01
JP6885629B2 (ja) 2021-06-16
US20220362211A1 (en) 2022-11-17
KR20210095721A (ko) 2021-08-02
KR102282794B1 (ko) 2021-07-27
CN114569606B (zh) 2024-04-19
CN109789127B (zh) 2022-03-25
US20190022062A1 (en) 2019-01-24
US10159660B2 (en) 2018-12-25
MX395539B (es) 2025-03-25
US20200253927A1 (en) 2020-08-13
CN109789127A (zh) 2019-05-21
KR20190025043A (ko) 2019-03-08
JP7182304B2 (ja) 2022-12-02
WO2018022771A1 (en) 2018-02-01
PH12019500070A1 (en) 2019-10-14
US12161626B2 (en) 2024-12-10
CA3029851A1 (en) 2018-02-01
MX2019000867A (es) 2019-09-16
CN114569606A (zh) 2022-06-03
JP2021107456A (ja) 2021-07-29
TWI857351B (zh) 2024-10-01
US11285132B2 (en) 2022-03-29
SG11201811661TA (en) 2019-01-30
TW202302089A (zh) 2023-01-16
JP7208659B2 (ja) 2023-01-19

Similar Documents

Publication Publication Date Title
TWI780061B (zh) 吲哚啉酮化合物之用途
CN109219594B (zh) 吲哚啉类似物及其用途
JP2023526283A (ja) 単独療法及び併用療法
JP2023508325A (ja) 組み合わせ
JP7631348B2 (ja) 組み合わせ
JP7750526B2 (ja) 組み合わせ
CN114302878A (zh) 酪氨酸激酶非受体1(tnk1)抑制剂及其用途
TW202328122A (zh) 降解Bcl-2家族蛋白的化合物及其在醫藥上的應用
HK40075992A (en) Uses of indolinone compounds
HK40075992B (zh) 吲哚啉酮化合物的用途
HK40006023A (en) Uses of indolinone compounds
HK40006023B (en) Uses of indolinone compounds
JP2023545498A (ja) Ｂｃｌ－２阻害剤と化学療法剤との組み合わせ
HK40067698A (en) Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
JP2023508324A (ja) 組み合わせ
HK40095032A (zh) 一种药物组合物及其在治疗癌症中的用途

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent